Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma.
Nishiyama A, Sakaguchi H, Yanagimura N, Suzuki C, Otani S, Tanimoto A, Yamashita K, Takeuchi S, Ohtsubo K, Ikeda H, Yano S. Nishiyama A, et al. Among authors: sakaguchi h. Oxf Med Case Reports. 2020 Dec 28;2020(12):omaa116. doi: 10.1093/omcr/omaa116. eCollection 2020 Dec. Oxf Med Case Reports. 2020. PMID: 33391772 Free PMC article.
Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab.
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Sakaguchi H, et al. Intern Med. 2022 Jan 1;61(1):75-79. doi: 10.2169/internalmedicine.7452-21. Epub 2021 Jun 26. Intern Med. 2022. PMID: 34176837 Free PMC article.
Clinical outcome of patients with inoperable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus Nab‑paclitaxel as a first‑line therapy: A retrospective analysis.
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Sakaguchi H, et al. Med Int (Lond). 2021 Jul 5;1(4):8. doi: 10.3892/mi.2021.8. eCollection 2021 Sep-Oct. Med Int (Lond). 2021. PMID: 38939364 Free PMC article. Review.
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers.
Kotani H, Yamano T, Boucher JC, Sato S, Sakaguchi H, Fukuda K, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Nishiuchi T, Oshima H, Oshima M, Davila ML, Yano S. Kotani H, et al. Among authors: sakaguchi h. Exp Hematol Oncol. 2024 Sep 27;13(1):94. doi: 10.1186/s40164-024-00563-x. Exp Hematol Oncol. 2024. PMID: 39334463 Free PMC article.
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, Sekiya T, Watanabe A, Tajima A, Shimaguchi C, Mizuguchi K, Ikeda H, Kinoshita M, Nakada M, Takeuchi S. Nishiyama A, et al. Among authors: sakaguchi h. Cancer Sci. 2024 Oct 25. doi: 10.1111/cas.16370. Online ahead of print. Cancer Sci. 2024. PMID: 39453824 Free article.
1,410 results